Tumor necrosis factor α in refractory asthma [11]

New England Journal of Medicine

Volumn 354, Issue 19, 2006, Pages 2074-2075

  Oliveri, Chiara ^a   Polosa, Riccardo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BRONCHODILATING AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ASTHMA; CLINICAL TRIAL; HUMAN; LETTER; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; DRUG ANTAGONISM; NOTE;

ASTHMA; BRONCHODILATOR AGENTS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646485416     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc060745     Document Type: Letter

References (3)

1. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 2006;354:697-708.
2. Russo C, Polosa R. TNF-α as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) 2005;109:135-42.
3. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:1012-8.